WANBURY LTD

Overview

WANBURY LTD is an active pharmaceutical ingredient (API) supplier with 20 active FDA Type II Drug Master Files, covering DEXTROMETHORPHAN HYDROBROMIDE; DIPHENHYDRAMINE CITRATE; DIPHENHYDRAMINE HYDROCHLORIDE; HYDRALAZINE HYDROCHLORIDE; IMIQUIMOD; MEFENAMIC ACID USP.

API / Drug Master Files

WANBURY LTD holds 20 active (43 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• RIVAROXABAN USPActive2025-04-04
• DEXTROMETHORPHAN HYDROBROMIDEActive2019-10-31
• HYDRALAZINE HYDROCHLORIDEActive2018-10-05
• IMIQUIMODActive2017-09-27
• SALSALATEActive2016-10-28
• PAROXETINE MESYLATEActive2016-05-14
• QUETIAPINE FUMARATEActive2013-11-20
• METFORMIN SR GRADE 70%Active2007-05-29
• DIPHENHYDRAMINE HYDROCHLORIDEActive2007-04-10
• PAROXETINE HYDROCHLORIDE HEMIHYDRATEActive2006-12-19
• METHOXSALENActive2006-12-11
• DIPHENHYDRAMINE CITRATEActive2006-11-15
• SERTRALINE HYDROCHLORIDE FORM IActive2006-10-10
• SERTRALINE HYDROCHLORIDEActive2005-12-13
• METFORMIN HYDROCHLORIDE DC GRADE - 95%Active2005-10-14

Showing 15 of 43 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to WANBURY LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.